**S2 Table:** Overview of differences between different subgroups in the study.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | DXA only | Baseline blood samples and/or follow-up blood samples | Baseline blood samples only | Follow-up blood samples |
|  |  |  | *p*1 |  |  | *p*2 |
| N | 407 | 469 |  | 168 | 301 |  |
| Sex (girls/boys) | 234/173 | 264/205 | 0.77 | 93/75 | 171/130 | 0.75 |
| Age | 11.0(1.6−21.7) | 11.3(4.0−20.8) | 0.22 | 11.6(5.4−20.8) | 11.2(4.0−20.3) | 0.32 |
| BMI SDS | 2.75(1.32−5.74) | 2.76(1.36−5.41) | 0.62 | 2.66(1.38−5.21) | 2.82(1.36−5.41) | 0.02 |
| %BF SDS | 1.38(0.17−2.69) | 1.40(0.01−2.44) | 0.81 | 1.37(0.01−2.27) | 1.44(0.08−2.44) | 0.15 |
| FFMI SDS | 1.16(-2.24−4.39) | 1.10(-1.51−3.15) | 0.25 | 1.03(-1.51-3.03) | 1.17(-1.19−3.15) | 0.53 |
| TC (mmol/L) | - | 3.9(1.7−6.5) | - | 3.9(2.2−6.1) | 3.9(1.7−6.5) | 0.91 |
| LDL (mmol/L) | - | 2.3(0.6−4.6) | - | 2.3(0.8−4.4) | 2.3(0.6−4.6) | 0.98 |
| HDL (mmol/L) | - | 1.1(0.6−2.3) | - | 1.1(0.6−2.3) | 1.1(0.6−2.2) | 0.67 |
| TG (mmol/L) | - | 0.9(0.1−4.9) | - | 0.9(0.1−3.6) | 0.8(0.1−4.9) | 0.93 |
| Treatment time(years) | 2.2(0.4−7.4) | 1.5(0.4−7.2) | 1.7\*10-5 | 1.5(0.4−5.3) | 1.5(0.6−7.2) | 0.12 |

*p*1 describes differences between baseline values in the patients with only DXA indices available, and the patients with both DXA indices and blood samples at baseline and/or follow-up available.

*p*2 describes differences between baseline variables in the patients with DXA and only baseline blood samples available compared to the patients with DXA and both baseline and follow-up blood samples available.

Differences in gender distribution investigated using Pearson’s Chi-squared test. Differences in numerical variables investigated using Wilcoxon signed rank test.